NatWest Share Price Today: Stock Slides 3.4% as Oil Shock and Revolut UK Bank Launch Weigh

March 12, 2026
NatWest Share Price Today: Stock Slides 3.4% as Oil Shock and Revolut UK Bank Launch Weigh

LONDON, March 12, 2026, 15:15 GMT

NatWest shares slipped 3.4% to 568 pence as of 1511 GMT on Thursday, deepening losses for the stock, which had been above 590p just two days back. That price leaves the lender sitting about 20% under its 705.4p peak from the past year. 1

This retreat stands out. NatWest was one of the UK’s standout bank trades—buoyed by fatter profit goals, a new buyback, and a ramp-up in wealth management. Despite Thursday’s slide, shares remain up roughly 36% over the last year. So the question now: how much of that bullishness sticks as conditions get tougher? 2

NatWest wasn’t the only name taking a hit on Thursday. The FTSE 100 slipped 0.4% during the morning session, oil bouncing back up toward $100 a barrel and traders dialing back expectations for rate cuts from the Bank of England. “The longer the disruption goes on, the greater the impact on energy prices and in turn global inflation,” said AJ Bell’s Danni Hewson. 3

The shift in the macro backdrop isn’t doing NatWest, a largely UK-focused lender, any favors. According to a RICS survey, new buyer enquiries across Britain’s housing market just slumped to their lowest since December. Rising oil and energy costs are raising the odds mortgage rates remain elevated, Tarrant Parsons, head of market research and analytics at the group, said. 4

Competition is on the move as well. On Wednesday, Revolut announced it had secured approval to operate as a British bank, with current accounts set to roll out within days—a direct push into NatWest’s turf, right up against Barclays and Lloyds. “The full licence will sharpen pressure on both traditional banks and the cohort of challenger banks,” said Elliot Reader, a director in Houlihan Lokey’s fintech group. 5

NatWest took a different tack. Last month, the bank posted a 24% jump in 2025 pretax profit, hitting 7.7 billion pounds, and set its sights even higher for returns, pushing the 2028 return on tangible equity target past 18%. That’s profit measured against shareholder capital. NatWest also rolled out a 750 million pound buyback. “Raising our ambition and sharpening our strategic focus,” CEO Paul Thwaite said. 2

Wealth is central to that strategy. NatWest is moving further into fee-driven wealth management, echoing recent pushes from HSBC and Lloyds as they hunt for revenue streams beyond straightforward lending. The bank’s planned £2.7 billion acquisition of Evelyn Partners would lift assets under management and administration to £127 billion—more than double the current figure—and, according to NatWest, deliver around £100 million in yearly cost savings. 6

From the outset, investors showed caution. Shares in NatWest dropped 4.5% on the day it announced the Evelyn acquisition. RBC Capital Markets’ Benjamin Toms described the transaction as “transformational”; Jefferies, by contrast, flagged that the price tag might drag earnings per share below a no-deal scenario until 2028. 6

A support level remains in place for now. NatWest’s planned final dividend of 23 pence per share goes ex-dividend on March 19—buyers after that date miss out on the payout. 7

The risk is right there: should oil prices remain elevated, housing cool further, and Evelyn’s integration drag on, shares could find it tough clawing back losses posted since February’s peak. 3

Technology News

  • Google Workspace adds Gemini AI to automate data entry with source citations
    March 12, 2026, 5:48 AM EDT. Google rolled out a new batch of Gemini-powered features across Docs, Sheets, Slides and Drive, aiming to automate routine work. Gemini will cite its sources after queries, with a sources tab showing where it drew flight confirmations and chats. In Sheets, users can describe tasks in plain language, skip exact formulas, and deploy an AI agent to fetch web data to fill cells, then summarize, categorize and chart results. You can chat with Gemini in Sheets to build custom reports. In Slides, natural-language prompts create slides and adjust layouts. Google also promotes personalized intelligence to tailor outputs to the user's needs. The updates position Google amid growing AI copilots while tying tools to users' files, emails and chats.

Latest Articles

International Consolidated Airlines Group SA stock falls as oil tops $100; IAG fuel hedges face fresh test

International Consolidated Airlines Group SA stock falls as oil tops $100; IAG fuel hedges face fresh test

March 12, 2026
IAG shares dropped 3.23% to 362 pence in London on Thursday as oil prices rose above $100 a barrel, raising concerns over airline fuel costs. The company said it remains well hedged and has no immediate plans to raise fares. British Airways ended winter flights to Abu Dhabi early, citing uncertainty. Package holiday group On the Beach suspended its profit forecast after a slowdown in Mediterranean bookings.
Beazley Plc Stock Price Holds Near 1,288p as Zurich Deal Gap Persists and JPMorgan Lifts Stake

Beazley Plc Stock Price Holds Near 1,288p as Zurich Deal Gap Persists and JPMorgan Lifts Stake

March 12, 2026
Beazley shares traded around 1,288 pence Thursday, below Zurich Insurance’s 1,335 pence-a-share offer. JPMorgan Chase raised its interest in Beazley to 5.5%, partly via derivatives. The 8.2 billion pound takeover, announced March 2, awaits shareholder, court, and regulatory approval, with a 25 pence dividend expected May 1. Zurich funded the deal partly through a 3.9 billion Swiss franc share sale.
GSK Stock Price Slips as Buyback Continues and Linerixibat Decision Looms

GSK Stock Price Slips as Buyback Continues and Linerixibat Decision Looms

March 12, 2026
GSK shares fell 0.7% to 2,051 pence after the company disclosed a buyback of 513,409 shares at an average price of 2,061.69 pence on March 11. The group recently licensed linerixibat to Alfasigma for up to $690 million and expects 2026 revenue growth of 3% to 5%. Investors remain focused on GSK’s pipeline and patent risks as linerixibat awaits approval.